Identification and Analysis of Immunomodulatory Molecules in Patients With Hematologic Disorders and Healthy Volunteers

Healthy Volunteers Clinical Trial

Official title:

Identification and Analysis of Immunomodulatory Molecules From Leukocytes in Patients With Hematologic Disorders and Healthy Volunteers

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00223483
• Other study ID #: HSC20040268H
• Status: Completed
• Start date: March 2005
• Est. completion date: July 14, 2021

Study information

• Verified date: July 2021
• Source: The University of Texas Health Science Center at San Antonio
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This research study goal is to analyze the plasma and the cells that make up part of the immune system. We want to learn how the plasma and cells work. These may influence why one person will develop an infection and another will not, or why one person develops severe symptoms of a disease while others remain without symptoms.

Description:

This research study goal is to analyze the plasma and the cells that make up part of the immune system. These cells, called white cells or leukocytes, are present in blood. We want to learn how these cells work to prevent infection and how they respond after an infection occurs. We also want to study certain molecules present on the plasma, on or in these cells, and the genetic material that allows these molecules to be made. These molecules may influence why one person will develop an infection and another will not, or why one person develops severe symptoms of a disease while others remain without symptoms. This study may increase our understanding of a variety of diseases including infections such as HIV, allergic diseases such as asthma, joint diseases such as rheumatoid arthritis, certain cancers, and the rejection process that sometimes occurs after transplantation of an organ.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 512
• Est. completion date: July 14, 2021
• Est. primary completion date: December 11, 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Must be able to give blood

• Must be able to give informed consent

• Signed, written informed consent

Exclusion Criteria:

• Individuals with a history severe anemia, inadequate venous access, severe blood or coagulation disorders.

• Pregnant women are excluded because it is a unique immunotolerant state and will alter the profile of immunomodulatory molecules.

Related Conditions & MeSH terms

• Healthy Volunteers
• Hematologic Diseases

Intervention

Genetic:
• Isolation of genomic DNA
One time blood draw

Locations

Country	Name	City	State
United States	Department of Veterans Affairs, South Texas Veterans Health Care System, Audie L. Murphy Memorial Veterans Hospital Division	San Antonio	Texas
United States	The University of Texas Health Science Center at San Antonio	San Antonio	Texas

Sponsors (2)

Lead Sponsor	Collaborator
The University of Texas Health Science Center at San Antonio	US Department of Veterans Affairs

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Repository collection of plasma and serum for future analysis.		12 years